Q-omics provides the consensus-scored ZNF346 profile across patient tissues and cancer cell-line models. ZNF346 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, ZNF346 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, ZNF346 protein abundance shows 32,663 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KICH, THCA, and PDAC as cancer lineages where ZNF346 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF346 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF346 survival associations across molecular data types. ZNF346 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF346 RNA expression–survival associations across cancer types. High ZNF346 expression shows unfavorable associations in KICH, LIHC, ACC and HNSC, but favorable associations in KIRC and BRCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for ZNF346 RNA expression.
This table summarizes ZNF346 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 8. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF346. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF346 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, COAD, KIRC and HNSC. The THCA box plot shows higher ZNF346 RNA expression in normal versus tumor tissue (log2 FC = −0.910, t-test p < 0.001).
This table shows molecular features associated with ZNF346 in patient tissues and cancer cell lines. In patient samples, ZNF346 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF346 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
